Bluejay Therapeutics Raises $182M in Series C for Clinical Pipeline Expansion

Bluejay Therapeutics, a pioneer in the field of innovative treatments, announced the successful completion of a $182 million Series C financing round. This significant capital will expedite the clinical development of BJT-778, a key treatment for chronic hepatitis D (HDV). Additionally, the funds will further the advancement of other promising candidates in Bluejay's extensive pipeline aimed at treating chronic hepatitis B (HBV).

BJT-778 has garnered PRIME designation from the European Medicines Agency (EMA), an acknowledgment stemming from favorable early results in Phase 1/2 studies for HDV. The Series C financing was co-led by Frazier Life Sciences and another life science-focused institutional investment firm. Contributions also came from both new and returning investors, including RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, and Unicorn Capital.

Following the successful financing round, Bluejay welcomed Daniel Estes, a General Partner at Frazier, to its Board of Directors. Dr. Keting Chu, the Founder and CEO of Bluejay Therapeutics, expressed profound gratitude for the strong support from both new and existing investors, highlighting their confidence in the company's strategic direction and the team's capability to achieve their mission. Dr. Chu emphasized that the funding not only supports the advancement of their lead assets through critical clinical trials but also enhances their ability to address substantial unmet medical needs in global health.

Bluejay Therapeutics is a privately held biopharmaceutical company dedicated to developing treatments for viral and liver diseases. The company's lead program, BJT-778, is a potentially best-in-class fully human IgG1 monoclonal antibody targeting the hepatitis B surface antigen (anti-HBsAg mAb). It is being developed for both chronic HBV and HDV. BJT-778 aims to deliver anti-HBV and anti-HDV benefits by neutralizing and eliminating HBV and HDV virions, as well as depleting HBsAg-containing subviral particles. This mechanism may help reconstitute a patient's antiviral immunity and contribute to a functional cure for chronic hepatitis B.

Beyond BJT-778, Bluejay is also advancing other innovative programs for chronic HBV. These include a proprietary TLR9 agonist named Cavrotolimod, and a liver-targeted transcript inhibitor, BJT-628. The goal of these programs is to achieve higher rates of functional cure for chronic hepatitis B.

Bluejay Therapeutics continues to make significant strides in the biopharmaceutical industry, focusing on developing transformative treatments for viral and liver diseases. The recent influx of funding and the expertise of new board member Daniel Estes further positions the company to achieve its ambitious goals and make a substantial impact on global health.